Thomas Breuer and colleagues at GlaxoSmithKline respond to Peter Doshi
| Autor: | Vincent Bauchau, Jens-Ulrich Stegmann, Tatjana Poplazarova, Thomas Breuer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Information Dissemination
business.industry Statement (logic) education MEDLINE General Medicine 030204 cardiovascular system & hematology Public relations 03 medical and health sciences Patient safety 0302 clinical medicine Influenza Vaccines Political science Influenza Human Premise Pandemic Humans Pandemrix Patient Safety 030212 general & internal medicine business |
| Zdroj: | BMJ. :k4116 |
| ISSN: | 1756-1833 0959-8138 |
| DOI: | 10.1136/bmj.k4116 |
| Popis: | We are writing to respond to The BMJ ’s feature article about the Pandemrix vaccine.”1 Our response focuses on some of the statements in the article as well the methodology on which the major premise of the article is based. The statement by The BMJ that the available safety data were not disclosed to the public by the authorities or by GlaxoSmithKline is incorrect. During the pandemic, safety data available to GSK and the company’s analyses of those data were shared regularly with the authorities through weekly teleconferences and monthly written periodic safety update reports. Summaries of the information relating to all pandemic vaccines used in Europe were made available to the public weekly on the European … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|